Diaceutics PLC Block Listing Return
07 Ottobre 2024 - 8:00AM
RNS Regulatory News
RNS Number : 0371H
Diaceutics PLC
07 October 2024
Diaceutics PLC
BLOCK LISTING RETURN
Belfast and
London, 7 October 2024 - Diaceutics PLC (AIM:
DXRX), a leading technology and solutions provider to the pharma
and biotech industry industry, gives the below information required
by Schedule 6 of the AIM Rules for Companies in connection
with the the UK and Global Share Incentive Plan for employees (the
"SIP") and the Employee Share Option Plan (the "ESOP") which
includes long term incentive awards.
|
Name of applicant:
|
Diaceutics PLC
|
|
Name of scheme:
|
UK and Global Share Incentive Plan for employees (the
"SIP") and the Employee Share Option Plan (the "ESOP") which
includes long term incentive awards.
|
|
Period of return:
|
From:
|
6 April 2024
|
To:
|
6 October 2024
|
|
Balance under scheme from previous return:
|
1,453,560 Ordinary Shares of £0.002 each
|
|
The amount by which the block scheme has been
increased, if the scheme has been increased since the date of the
last return:
|
N/A
|
|
Number of securities issued/allotted under
schemes during period:
|
30,149 Ordinary Shares
|
|
Balance under scheme not yet issued/allotted at end
of period
|
1,423,411 Ordinary Shares
|
|
Number and class of securities originally listed and the
date of admission
|
1,500,000 Ordinary Shares on 6 October 2023
|
|
Total number of securities in issue at the end of the
period
|
84,726,935 Ordinary Shares of £0.002
each
|
|
Name of contact:
|
Nick Roberts
|
|
Telephone number of contact:
|
As below
|
|
|
|
|
|
Enquiries:
|
Diaceutics
PLC
|
Tel: +44 (0)28 9040 6500
|
|
Nick Roberts, Chief Financial
Officer
|
investorrelations@diaceutics.com
|
|
|
|
|
Canaccord
Genuity Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7523 8000
|
|
Simon Bridges, Andrew Potts, Harry
Rees
|
|
|
|
|
|
Alma Strategic
Communications
|
Tel: +44(0)20 3405 0205
|
|
Caroline Forde, Kinvara Verdon
|
diaceutics@almastrategic.com
|
About Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease
outcome.
We provide the world's leading
pharma and biotech companies with an end-to-end commercialisation
solution for precision medicines through data analytics, scientific
and advisory services enabled by our platform DXRX - The
Diagnostics Network®.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRFLFVLIALSIIS
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Feb 2024 a Feb 2025
